Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Fox Chase Cancer Center Identifier:
First received: June 5, 2003
Last updated: July 10, 2013
Last verified: July 2013

RATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining epirubicin with rituximab may kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combining epirubicin with rituximab in treating patients who have relapsed or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

Condition Intervention Phase
Biological: rituximab
Drug: epirubicin hydrochloride
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Epirubicin and Rituximab in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma and CLL

Resource links provided by NLM:

Further study details as provided by Fox Chase Cancer Center:

Enrollment: 5
Study Start Date: March 2003
Study Completion Date: August 2005
Primary Completion Date: August 2005 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the response rate, time to progression, and overall survival of patients with refractory or relapsed B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia treated with epirubicin and rituximab.
  • Determine the toxicity of this regimen in these patients.
  • Determine the pharmacokinetics of this regimen in these patients.

OUTLINE: This is a non-randomized, open-label, multicenter study.

Patients receive epirubicin IV over 3-5 minutes once weekly for 6 weeks. Patients also receive rituximab IV on weeks 2 and 5 during course 1 and then on weeks 1 and 4 for all remaining courses. Treatment repeats every 8 weeks for a maximum of 3 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months until disease progression.

PROJECTED ACCRUAL: A total of 18-38 patients will be accrued for this study within 2.5-3 years.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed B-cell non-Hodgkin's lymphoma (any grade) or chronic lymphocytic leukemia meeting 1 of the following criteria:

    • Primary refractory disease
    • Disease progression after at least 1 but no more than 4 prior cytotoxic chemotherapy regimens

      • Rituximab administered alone is not considered 1 prior regimen
      • High-dose chemotherapy with stem cell support is considered 1 prior regimen
  • Bidimensionally measurable or evaluable disease outside prior irradiation port
  • No clinical evidence of CNS involvement



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified


  • Neutrophil count at least 2,000/mm^3*
  • Platelet count at least 100,000/mm^3* NOTE: *Unless due to bone marrow involvement


  • Bilirubin no greater than 1.5 mg/dL
  • SGOT and SGPT no greater than 2 times upper limit of normal (ULN)


  • Creatinine no greater than 2 times ULN


  • No unstable angina
  • No uncontrolled congestive heart failure
  • LVEF at least 45%


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 6 months after study treatment
  • HIV negative
  • No other concurrent primary malignancy except basal cell or squamous cell skin cancer, carcinoma in situ, or localized solid tumors cured more than 5 years ago
  • No acute infection requiring systemic therapy
  • No confusion, disorientation, or major psychiatric illness that would preclude understanding of informed consent


Biologic therapy

  • See Disease Characteristics
  • At least 4 weeks since prior biologic therapy


  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
  • Prior cumulative doxorubicin dose no greater than 6 courses at 50 mg/m^2

Endocrine therapy

  • Not specified


  • See Disease Characteristics
  • No prior radiotherapy to the entire pelvis
  • At least 4 weeks since prior radiotherapy


  • Not specified


  • More than 7 days since prior cimetidine
  • No concurrent cimetidine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00062296

United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Sponsors and Collaborators
Fox Chase Cancer Center
National Cancer Institute (NCI)
Study Chair: Mitchell R. Smith, MD, PhD Fox Chase Cancer Center
  More Information

Responsible Party: Fox Chase Cancer Center Identifier: NCT00062296     History of Changes
Other Study ID Numbers: FCCC-02025
CDR0000304711 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: June 5, 2003
Last Updated: July 10, 2013

Keywords provided by Fox Chase Cancer Center:
B-cell chronic lymphocytic leukemia
refractory chronic lymphocytic leukemia
recurrent adult diffuse large cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent adult diffuse small cleaved cell lymphoma
recurrent adult Burkitt lymphoma
recurrent adult immunoblastic large cell lymphoma
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent grade 3 follicular lymphoma
recurrent mantle cell lymphoma
recurrent adult lymphoblastic lymphoma
recurrent marginal zone lymphoma
recurrent small lymphocytic lymphoma
extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
nodal marginal zone B-cell lymphoma
splenic marginal zone lymphoma

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 25, 2017